{"entity":{"id":"nct06177522","kind":"trial","name":"Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of adebrelimab, nab-paclitaxel and gemcitabine in pancreatic cancer, run by Jinling Hospital, China, not yet recruiting.","summary":"Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT06177522 by Jinling Hospital, China, with a registry enrolment figure of 30 participants, started 2025-11-30 and due to reach its primary completion in 2027-12-30. Interventions recorded: Adebrelimab; albumin-bound paclitaxel; Gemcitabine. Conditions listed: Pancreatic Cancer; Neoadjuvant Therapy. Primary outcome: R0 removal rate; pCR rate. Pancreatic eligibility wording from the registry: \"Patients with resectable pancreatic adenocarcinoma confirmed by histopathology or cytology (CA19-9 \\> 150 U/ml);\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06177522","url":"https://clinicaltrials.gov/study/NCT06177522"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["adebrelimab","nab-paclitaxel","gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06177522","phase":"2","setting":"A Single-arm, Single-center, Exploratory Study of Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer","sponsor":"Jinling Hospital, China","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06177522/","neighbours":{"cancer":[{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}